And Brian. good you, afternoon. thank Well,
our diversified pleased report to a financial demonstrate June and to are effectively results continue as company. grow to our that quarter businesses services ability execute We healthcare
strategic continued strength Our our demonstrating ahead our fiscal first priorities, our of quarter results reflecting against are of the expectations, operations. progress
with Let our today to focus portfolio. before updates I a ongoing our to me our Europe first begin quarter start and with few results. reviewing streamline want company
retail operations Denmark remaining subject several our sell joint with Group European operationally sales completed actions other exemplified we of by few we transaction solutions ensuring Austrian the The actions April focused our delivering effectively, in in taken of well. past that customers’ share are we've organization challenges. in close German UK of sale in the of efficient and business July second is years, the biggest Over streamline is deliberate more XXXX, capital This to of deploy our solving our in entered is to business. date, reviews. the will agreements exit in divested In of or sale and the half countries the XXXX, announced fiscal successfully And Phoenix fiscal transactions. our anticipate the we to to the in it countries in business In the we the assets that closed sell business Since of XX the fourth wholesale To July XXXX. of following completed into venture. we've to proceeding operations in of of XXXX operations. XXXX, our completed XX we've region time quarter We which European certain in operate. also regulatory the
to strategic in exit to not sell. only yet we've continue remaining the country an to operations explore Norway, agreement into that alternatives entered We
operating European For Phoenix contribute XXXX, approximately will share, which accretion transaction to accounting $X.XX the we resulting of operations fiscal from anticipate per profit the the remaining with a through our held-for-sale includes Group. $X.XX adjusted diluted
aligns Institute, the in In offset Oncology calendar Sarah outlook. McKesson’s and including transaction of year the Biopharma our per growth took European allows acquisition our Cannon deploy repurchases to assets announced by important do Europe of adjusted Oncology venture December important improve in XXXX impact We medicine another our our Genospace, have HCA Research Healthcare’s focus close of agreement to an regulatory share setting. again, supports As joint services the ecosystems. combination will we to Sarah to a ecosystem. on every Day, this discussed anticipate operations to is an June, a this quarter to in subject transaction complements Cannon's dilution strategic earnings not our Research through to these It our We vision The and US and share anticipated capital Exiting fiscal end combining our step divestitures. personalized priority, form we the approval. platform. from The XXXX, review strategic priorities. operations. Oncology existing on intend at It expanding Investor material care to resulting us
the July fiscal remarks. of of Next, our to as earlier, for COVID-XX later of the guidance I centralized contract government serve storage kitting was distributor was Brian in mentioned will and extended contract through extended the my And January with discuss through as the of U.S. recently impact XXXX ancillary XXXX. supplies a for vaccines XXXX.
Finally, point securities second will out of million. impact only for GAAP I additional in item of proceeds equity investments exited that McKesson XXXX, one our July one its quarter In want of $XXX to fiscal results.
will We a gain in only income GAAP quarter. recognize other within the second
reflecting of a growth in to billion the unless billion will otherwise. results, revenues refer International divestiture $XX.X state $X a a comments My segment, as to Consolidated fiscal in was by decrease basis, of result adjusted Pharmaceutical review increased segment, the quarter, today Gross a of on process. revenues U.S. X%. I lower XXXX now partially year-over-year for first profit the offset the Moving results. European our our quarter X%, of
gross our segment products the specialty and increased quarter a Solution divestitures in Excluding due impact European our the segment. the in Technology increased business divestitures Pharmaceutical to X% and XX% in Operating Prescription result International profit growth of operations by our segment. volume expenses segment, Medical-Surgical Solutions organic in completed in of a completed U.S. decreased growth
of X% Wrapping and million average XX.X% a services X% up our year. Prescription effective gains due fiscal $X.XX, the the net improved compared share investments, products Technology adjusted Interest first decrease first related And debt increase associated When was to losses was million, consolidated in equity As with Pharmaceutical was transaction first the the tax $XX volumes led segment. year-over-year. share a and outstanding the the rate result decrease XXX.X year-over-year and impact billion the profit Solution quarter of increased prescription operating operating quarter for distribution from in to XXXX quarter, the of quarter. XX% throughout $X.X XXXX. year-over-year. excluding by profit reduction a of U.S. of an for in were McKesson quarter; growth COVID-XX Ventures' of quarter and expense related shares the weighted X% Overall, repurchases prior results, X% a fiscal of diluted earnings increase per resulting an and to diluted was
Now product which resulting can for COVID-XX be starting in $XX.X systems, year-over-year, of and twelve billion, Revenues provided to through onto quarter contract distribution share led specialty from XXXX. is seven vaccine was growth, from vaccine lower our partially products to with partially $X.XX quarter improved compared is volumes, volumes Ontada, contribution customers in Pharmaceutical. per U.S. first which increase performance led The the of government our generic fiscal on approximately share which distribution. providers segment with and of account branded by U.S. the offset a quarter, increased the of launches first found market benefit offset results, in of XX% $X.XX retail slides by million were COVID-XX per increased generic an and by of by profit specialty Operating and which distribution to to $XXX growth X% conversions. national health
Ontada. Pharmaceutical from the profit impacted launches vaccine improved segment the delivered distribution, mix. operating lower generic Operating modestly margins benefited COVID-XX the in performance U.S. growth quarter timing Excluding in of X%. the and the were Results of by the of quarter impact of
X% robust growth, systems retail health year-over-year overall from partially contributed XX% growth account top-line the in providers the multi-specialty to by which were national growth. customer As offset
our and quarter. continued Next patients. of noted Solutions Prescription and suite strong continue be stakeholders, for Technology is adherence segment to providers solutions scale including delivered The affordability earlier, offerings to our across were reflecting Revenues driven Operating Response acceptance year-over-year all and of biopharma volume delivered Brian another increased to of which billion services, expanded payers. service access, adherence continued technology to $X.X set favorable XX% a logistics revenues. profit and growing by the an from increased third-party XX% access, market includes and services growth increase million affordability $XXX solutions. biopharma strong
care in care Medical-Surgical tests to demand ancillary Revenues profit as billion in COVID-XX U.S. contract tests down and contributed growth of in the primary business; kitting, contribution lower government’s and higher of for in Operating million volumes primary the for illness with increased quarter X% and respiratory $X.X of were to Moving flu COVID-XX by to first approximately testing incidents lower from X% distribution in contribution of supplies Solutions. and government vaccine year-over-year driven and business. the business, across patient The strength storage distribution our partially in COVID-XX anticipated total the fiscal storage the $XXX increase a to sales U.S. of offset share primary visits in $X.XX greater kitting, provided from the improve program. care an for per of quarter the ancillary per XXXX. supplies compared benefit $X.XX share the
the delivered the Excluding of profit Solutions these COVID-related of XX%. segment Medical-Surgical growth impact operating items,
Next, a of billion. $X.X operating FX Revenues of a which billion, $XXX International were operating adjusted An a was XX%. XX%. let revenues An an million, decrease XX%. results. were address $XXX decrease basis, was me On our profit profit decrease million, was of $X.X
the quarter Austrian Our UK reflect businesses. in from McKesson divestitures results impact and first the
on Corporate. Moving to
change Our In gain that investment expenses. previous we in anticipate the quarter; Corporate expenses the year-over-year. of incurred litigation million XXXX million, to opioid-related quarter, litigation and $XXX expenses $XX approximately lower we decrease healthcare the $XX million. related a receivable fiscal our would tax X% expenses opioid-related litigation were opioid-related of a be first We recognized
the $XX to million $X quarter portfolio, of the in gains first to XXXX. net investments within McKesson losses fiscal compares net million equity which had Ventures of During of the quarter, we related approximately
timing in may by as investments impacts It’s not consolidated guidance. gains be influenced And, which when results magnitude and gains for the reminder, a continue a losses quarter-to-quarter. McKesson the portfolio As include losses, on result, to And can of individual performance occur. our result in on will has investment practice can may each of our or the been predict McKesson’s companies and Ventures to estimates our portfolio investment. McKesson and therefore, vary difficult each Ventures
position, our to turn Slide me can on be Let which cash XX. found
resulting As be by cash in and the and our position, We working can a cash flow reminder, impacted free from timing quarter and metrics billion equivalents. vary cash cash $X.X capital quarter-to-quarter. ended with
million the quarter, investments growth a our and expenditures, $XXX During to in and we capital includes data analytics made services technology, biopharma of ecosystems. support which priorities, including our oncology
For $X the quarter, we had negative free billion. flow of
to quarter, Board returned cash billion of July, billion our a also dividend repurchase June We included of share dividend billion to increase share brings per of shareholders $X Directors and And which $X.X $XX also approved $X.XX authorization the payments. $X.X to XX% repurchase quarterly approved during billion. total million In which the authorization, a the board share. share our remaining $X to repurchases in new
have the remains repurchases unchanged. that actions demonstrate XXXX against Board of and priorities. our in share confidence the management the per fiscal execution These Directors guidance Our strategic
through affordability areas and center principles our continues services, Our place. oncology of and adherence firmly deployment capital biopharma M&A access internally We focus expansion in by solutions. investing including growth the to prioritize and of on remain the
by piece through maintenance the strong investment And our continued share we’ll and sheet credit return is balance shareholders growing underpinned rating. framework combination a third focuses the to of on a and to grade the financial position, our Next, repurchases. capital dividend which of of
basis presentation. additional walk consolidated supplemental through X% our I’ll to to COVID-XX XX these outlook, reported the X% slide and guidance compared investments. guidance. to impacts you to items government’s XX%. with be XXXX list tests profit XX with a turn decline and a found can X% beginning We or of fiscal fiscal distribution fiscal starting the Ventures and programs, McKesson our Slides details XXXX view. revenue assumptions U.S. equity associated growth operating on profit adjusted me On of through net key XXXX. XXXX related to consolidated full kitting with A COVID-XX our flat gains vaccine to losses anticipate When to and excluding increase operating centralized X% assumes the fiscal Let
in of $XXX quarter. to million, net impact We losses corporate million with expenses $XXX also associated includes investments first in range anticipate of McKesson equity the Ventures the the which
modestly current now range expense $XXX interest environment, anticipate million $XXX the to we to and of increase in Given interest rate the be million.
unchanged. continued distribution and year Based effective quarter are COVID-XX tax on solid results our distribution full approximately in XX% ancillary remains the operating anticipated segment and with the U.S. performance extensions vaccine of first and rate government storage supplies. contract XX% each of Our for to kitting, the
increasing our to of the from XXXX for $XX.XX $XX.XX to fiscal to guidance are range We range $XX.XX previous $XX.XX.
outlook Our the fiscal XXXX previously deliver and to sustainable it demonstrates targets, aligns commitment with the communicated growth long-term growth.
to U.S. McKesson kitting, following a in of Medical-Surgical our ancillary distribution related also Solutions to includes of associated the to revised the in in COVID-XX with storage contribution net equity $X.XX related Ventures Our guidance and of U.S. segment. $X.XX to attributable supplies $X.XX $X.XX our $X.XX $X.XX items. Pharmaceutical tests to $X.XX to the and losses segment, investments. government’s distribution vaccine
items equity and guidance related fiscal fiscal COVID-XX Ventures results. McKesson from these and of XXXX from and impacts XXXX the losses net investments both Excluding gains
XX% the earnings approximately over XXXX fiscal growth to guidance Our adjusted XX% year. indicates prior
In U.S. Pharmaceutical X% anticipate and of core to to to the efficiency platform oncology now XX% outlook operating year-over-year. We and increase first ecosystem. to performance durability segment our in revenue growth solid the X% segment, profit Moving in operating our to approximately of reflects continued development our decline outlook. quarter, XX% the distribution the the reported
we we anticipate the growth XX%, In X% reported revenue volumes. modestly U.S. growth COVID-XX $X.XX which growth, to reflects anticipate anticipate now approximately for XX%. X% X% segment, operating revenues above XX% profit contract outlined a is Medical-Surgical and includes XX% solution of vaccine distribution the operating result of segment, to When Solutions vaccine In profit we X% Technology to of government, $X.XX target. XX% previously extension. to to excluding Solutions outlook the growth Our X% decrease to affordability distribution, increased COVID-XX related which the impact Prescription the operating long-term to to and of profit
approximately and for to includes January the and incorporates to with COVID-XX the of U.S. $X.XX XXXX. of storage the which tests $X.XX outlook government the ancillary related government, Our distribution supplies contract kitting, U.S. extension to
Medical-Surgical Excluding COVID-XX operating related profit to to XX% from year-over-year And these we’ve XX% the we decline items, fiscal revenues and the increase International by in transactions to impact anticipate this And loss XX% to decline operating a date. decrease XX%. we segment, profit anticipate to includes to closed to operating XXXX. those and to profit during by of expect XX%. close continue businesses we of to And XX% finally, contribution
Let anticipate outlook capitalized few $X.X we with comments acquisitions on and of me and billion, expenses. flow property which conclude cash free XXXX, our capital flow net approximately $X.X fiscal software to fiscal of deployment. In a to continue billion is cash XXXX
reminder, flows impacted and a resulting metric quarter-to-quarter. XXXX working European working capital including be the can from cash these activity. be are cash may vary fiscal As flows capital and by Each flows our by metrics cash progression of timing in divestiture impacted
assumption plans of $X.X of Our buyback outlook fiscal shares. divestitures. associated impact XXXX the with of mitigating share the European approximately is billion Significant portion repurchase incorporates year-over-year
solid million. approximately fiscal XXXX activity average a pleased $XXX for result weighted As to wrap are diluted estimate million the shares $XXX to our To of up be year. the in we to we repurchase with range of the outstanding share fiscal start
on deliver to company. diversified strategy as healthcare services continue We our growth
talented continue to associates performance. deliver Our exceptional
also operating dedication a And of represents in performance financial environment. their execution their and the reflects resiliency portfolio. our quarter it first Our dynamic
the first questions. it positions long-term strategy combination continued let execution our McKesson growth to that our sustainable financial for back performance, performance and quarter deliver creation. to the solid With ahead, and turn operator your me value shareholder Looking of
